MDS UK grows its team to increase its support to patients

The MDS UK Committee is pleased to welcome two new members to the charity team: Lizzie Marshall, and Chris Fryer. Both Lizzie and Chris have experience in the Non-Profit and Charity Sector. Lizzie is a trainee psychotherapist with a background in the performing arts. She works supporting vulnerable people with learning difficulties alongside her new […]

Read full story

PANTHER: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Higher risk MDS, CMML, low blast count AML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Azacitidine, Pevonedistat
Read full story

BRIGHT: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Previously untreated higher-risk MDS, AML or CMML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Glasdegib, Azacitidine
Read full story

FT-2102: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome with an IDH1 R132 mutation
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: FT-2102
Read full story

URGENT: A father of 7, recently diagnosed with MDS needs your help

This is an urgent appeal for stem cell donors, for a Dad who was diagnosed in July 2018 with a high-risk form of MDS, Myelodysplastic Syndromes, a rare form of blood cancer, that can progress to leukaemia. Damian is a father of 7 lovely children – aged 4 to 27.  Damian was told that without treatment, […]

Read full story

MEDI4736

  1. SUB-TYPE OF MDS: Patients who have previously received a hypomethylating agent (eg. Azacitidine, Decitabine)
  2. SEVERITY OF MDS: Intermediate-2 or High risk
  3. NAME OF DRUG: Durvalumab, Tremelimumab, Azacitidine
  4. Read full story

How is Quality of Life in patients with Myelodysplastic Syndromes (MDS) measured?

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? In this article David Steensma, MD FACP at the Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts USA discusses how to incorporating the Patient’s Voice into MDS Care and Research. Measuring quality of life: how to capture […]

Read full story
Free donations by shopping